Filing Details
Bicara Therapeutics Inc. (NASDAQ:BCAX) filed a Form 8-K with the Securities and Exchange Commission on July 28, 2026, disclosing a material event.
8k filedNASDAQ:BCAX
Bicara Therapeutics Inc. (BCAX) Reports Material Event to SEC
Filing Details Bicara Therapeutics Inc. (NASDAQ:BCAX) filed a Form 8-K with the Securities and Exchange Commission on July 28, 2026, disclosing a material event. Market Context…
Market Context
Bicara Therapeutics Inc.'s stock currently trades at $26.88 with a market capitalization of $1.0B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Bicara Therapeutics Inc.'s stock.
All SEC filings for Bicara Therapeutics Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View BCAX Stock Page
Frequently Asked Questions
Where can I read BCAX's SEC filings?
Browse all filings on our BCAX SEC filings page.
What types of SEC filings does Bicara Therapeutics Inc. file?
Public companies like Bicara Therapeutics Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.